<table id="t305" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6: (R)-Albuterol Exposure in Adults and Pediatric Subjects (6-11 years)
</caption>
<col align="left" span="1" width="22.618%"></col>
<col align="left" span="1" width="12.216%"></col>
<col align="left" span="1" width="13.241%"></col>
<col align="left" span="1" width="12.216%"></col>
<col align="left" span="1" width="12.216%"></col>
<col align="left" span="1" width="3.063%"></col>
<col align="left" span="1" width="12.216%"></col>
<col align="left" span="1" width="12.216%"></col>
<tbody>
<tr>
<td></td>
<td>Children 6-11 years
</td>
<td></td>
<td>Adults ≥12 years
</td>
</tr>
<tr>
<td>Treatment
</td>
<td>XOPENEX<br/>0.31 mg
</td>
<td>XOPENEX<br/>0.63 mg
</td>
<td>Racemic<br/>albuterol<br/>1.25 mg
</td>
<td>Racemic<br/>albuterol<br/>2.5 mg
</td>
<td></td>
<td>XOPENEX<br/>0.63 mg
</td>
<td>XOPENEX<br/>1.25 mg
</td>
</tr>
<tr>
<td>AUC<sub>0-∞</sub> (ng•hr/mL) <sup>c</sup>
</td>
<td>1.36
</td>
<td>2.55
</td>
<td>2.65
</td>
<td>5.02
</td>
<td></td>
<td>1.65 <sup>a</sup>
</td>
<td>3.3 <sup>b</sup>
</td>
</tr>
<tr>
<td>C<sub>max</sub> (ng/mL) <sup>d</sup>
</td>
<td>0.303
</td>
<td>0.521
</td>
<td>0.553
</td>
<td>1.08
</td>
<td></td>
<td>0.56 <sup>a</sup>
</td>
<td>1.1 <sup>b</sup>
</td>
</tr>
<tr>
<td>
<paragraph>
<sup>a</sup> The values are predicted by assuming linear pharmacokinetics
</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>
<sup>b</sup> The data obtained from <linkhtml href="#t304">Table 5</linkhtml>
</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>
<sup>c</sup> Area under the plasma concentration curve from time 0 to infinity
</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>
<sup>d</sup> Maximum plasma concentration
</paragraph>
</td>
</tr>
</tbody>
</table>